Therapy Directory

Elranatamab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Elranatamab as a study intervention. Browse Elranatamab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Local indexed summaries

Local recruiting

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Showing 1–12 of 36 matching trials for Elranatamab.

Live ClinicalTrials.gov results.

Top conditions

Multiple Myeloma 19 Multiple Myeloma (MM) 3 Refractory Multiple Myeloma 2 Relapse Multiple Myeloma 2 Relapsed Refractory Multiple Myeloma (RRMM) 2 AL Amyloidosis 1

Top sponsors

Pfizer 7 Massachusetts General Hospital 3 M.D. Anderson Cancer Center 2 SCRI Development Innovations, LLC 2 AstraZeneca 1 C4 Therapeutics, Inc. 1

Top locations

Boston, Massachusetts 10 Miami, Florida 8 New York, New York 8 Atlanta, Georgia 7 Houston, Texas 7 Coral Gables, Florida 5

Live official records

Open in full search

Conditions: Multiple Myeloma
Interventions: Elranatamab (PF-06863135); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 37
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 17 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 17
States / cities: Jupiter, Florida • Lincoln, Nebraska • Reno, Nevada + 10 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Elranatamab; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM), Extramedullary Disease in Multiple Myeloma, Paramedullary Disease, PMD
Interventions: Elranatamab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma
Interventions: elranatamab, Isatuximab SC, Isatuximab SC-OBDS; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Elranatamab, Iberdomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more

Conditions: Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
Interventions: Elranatamab, Tocilizumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Denver, Colorado • Columbia, Maryland • Las Vegas, Nevada + 2 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Mezigdomide, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • New Haven, Connecticut • Hackensack, New Jersey + 1 more

Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 100
States / cities: Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Daratumumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 26
States / cities: Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more

Conditions: AL Amyloidosis
Interventions: Elranatamab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • Cleveland, Ohio

About this Elranatamab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Elranatamab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Elranatamab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Elranatamab clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Live official records

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

ELISA in Relapsed/Refractory MM

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Elranatamab in R/R Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

About this Elranatamab clinical trials directory page